New CDMO, backed by private equity player, to manufacture biologics

New CDMO TriPharm Services has picked Morrisville, North Carolina, to build its 32,000-square-foot facility for manufacturing biologics and other sterile injectables. (TriPharm Services)

Private equity player Ampersand Capital Partners, which this year sold Brammer Bio for $1.7 billion, is investing in another U.S. CDMO, this one targeted at sterile injectables.

TriPharm Services Wednesday announced it would set up a 32,000-square-foot facility in Morrisville, North Carolina, with four isolator filling suites and eight clean rooms to manufacture biologics. It said it expects the site to be fully operational by the second quarter of 2020. Terms of the investments were not released.

Ampersand Capital Partners has been busy this year. In March, it sold Brammer Bio for $1.7 billion to Thermo Fisher Scientific, giving Thermo Fisher entry into the growing gene and cell therapy market. Cambridge, Massachusetts-based Brammer has expertise in viral vector manufacturing. Thermo Fisher has been expanding its contract manufacturing operations since acquiring Patheon in 2017.

Just weeks after it sold Brammer, Ampersand Capital bought Germany-based Vibalogics. The 50-person CDMO specializes in viruses and has a 27,000-square-foot facility in Cuxhaven, Germany. Terms of the deal were not disclosed.

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.